Anti-androgen effects of extracts and compounds from Ganoderma lucidum.
The 30% EtOH extracts of Ganoderma lucidum Fr. Karst (Ganodermateceae) showed weak 5alpha-reductase inhibitory activity and binding ability to androgen receptor. When LNCaP (lymph-node carcinoma of the prostate) cells were treated with the EtOH extracts, cell proliferation was inhibited. Treatment with the extracts significantly inhibited the testosterone-induced growth of the ventral prostate in castrated rats. These results showed that G. lucidum might be a useful ingredient in the treatment of androgen-induced diseases, such as benign prostatic hyperplasia or prostate cancer. From the 30% EtOH extracts, we isolated ganoderiol F, which showed binding activity to androgen receptor and inhibited LNCaP cell proliferation, as one of the active compounds in the 30% EtOH extracts.
Liu
Jie
J
Department of Forest and Forest Products Science, Faculty of Agriculture, Kyushu University, Fukuoka 812-8581, Japan.
Tamura
Sadaaki
S
Kurashiki
Kenji
K
Shimizu
Kuniyoshi
K
Noda
Kiyoshi
K
Konishi
Fumiko
F
Kumamoto
Shoichiro
S
Kondo
Ryuichiro
R
D000726:Androgen Antagonists / Q000737:chemistry / Q000494:pharmacology*; D000818:Animals; D045744:Cell Line, Tumor; D006801:Humans; D008297:Male; D009930:Organic Chemicals / Q000737:chemistry / Q000494:pharmacology; D051381:Rats; D020940:Reishi / Q000737:chemistry*; D014315:Triterpenes / Q000302:isolation & purification / Q000494:pharmacology
D000726:Androgen Antagonists; D009930:Organic Chemicals; D014315:Triterpenes; C513307:ganoderiol F